HIGHLIGHTS
- who: Suzanne George from the Medical Oncology, Dana-Farber Institute, Boston, MA, United States Medical Oncology, Stanford University, Stanford, CA, United States have published the research work: Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour, in the Journal: (JOURNAL)
- what: The authors report the phase I study results of intrapatient dose escalation (IPDE) in patients with GIST treated across second third and later lines of therapy. This study aimed to determine the efficacy, PK and safety of ripretinib dose escalation after disease progression.
- how: A . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.